Download PDF
Thromb Haemost 1991; 65(05): 573-577
DOI: 10.1055/s-0038-1648192
Original Article
Schattauer GmbH Stuttgart

The Effect of Agonists and Antagonists of Platelet Aggregation on von Willebrand Factor-Mediated Platelet Agglutination

Jean McPherson
*   The Faculty of Medicine, University of Newcastle, Newcastle, N.S.W., Australia
,
Marjorie B Zucker
**   The Department of Pathology, New York University Medical Center, New York, NY, U.S.A
,
Evelyn A Mauss
**   The Department of Pathology, New York University Medical Center, New York, NY, U.S.A
,
Sandra Brownlea
*   The Faculty of Medicine, University of Newcastle, Newcastle, N.S.W., Australia
› Author Affiliations
Further Information

Publication History

Received 14 June 1990

Accepted after revision 14 December 1990

Publication Date:
24 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Ristocetin-induced platelet agglutination (RIPA) in EDTA-treated citrated platelet-rich plasma was reduced to 49 ± 11% by 1.25 ΜM ADP, 41 ± 14% by 1 ΜM A 23187, and 26 ± 7% by 0.1 Μg/ml platelet activating factor (PAF). The effect of 5-110 ΜM epinephrine was not dose-dependent, but varied between donors, with RIPA from 56-100% of the control. The inhibitory effects of these agonists were not altered by prior treatment of platelets with aspirin. Prior addition of 200 ΜM ATP (an ADP receptor antagonist acting at both high and low affinity ADP receptors) prevented the inhibitory action of ADP but not that of A 23187 or PAF, suggesting that the inhibitory actions of the latter are not mediated by released ADP. As 700 ΜM 8-bromoadenosine 5-diphosphate (an ADP receptor antagonist acting mainly at the high affinity receptor) did not prevent ADP-induced inhibition of RIPA, interaction of ADP with the low affinity receptor is presumably responsible for its inhibitory action. As A 23187, but not phorbol myristate acetate (0.1 ΜM) inhibited RIPA, an increase in intracellular calcium ions rather than direct stimulation of protein kinase C appears to mediate agonist-induced inhibition. Cytochalasin B (10.5-21 ΜM), dibucaine (0.5-1 mM), and prostaglandin E1 (25 nM), added before or after the agonist, prevented or reversed ADP-, A23187-, and PAF-induced inhibition of RIPA, suggesting that the state of the platelet cytoskeleton affects inhibition. N-ethylmaleimide (0.25-0.5 mM), an agent that can penetrate cell membranes and block sulphydryl groups, prevented or reversed ADP, A 23187- and PAF-induced inhibition of RIPA, but 0.5 mM dithionitrobisbenzoic acid, a non-penetrating sulphydryl blocker, had no effect. Diamide (0.1-0.5 mM), an agent that can crosslink cytoskeletal proteins by oxidation of sulphydryl groups, reduced RIPA. Thus an increase in intracellular calcium ions with resultant cytoskeletal changes and reorganisation of intracellular sulphydryl groups may mediate the inhibitory action of agonists on RIPA.

 

  • REFERENCES

  • 1 Jenkins CSP, Phillips DR, Clemetson KJ, Meyer D, Larrieu M-J, Lüscher EF. Platelet membrane glycoproteins implicated in ristocetin-induced aggregation. J Clin Invest 1976; 57: 112-114
    CrossrefPubMedGoogle Scholar
  • 2 Girma J-P, Meyer D, Verweij CL, Pannekoek H, Sixma JJ. Structure-function relationships of human vWf. Blood 1987; 70: 605-611
    PubMedGoogle Scholar
  • 3 Allain JP, Cooper HA, Wagner RH, Brinkhous KM. Platelets fixed with paraformaldehyde: a new reagent for assay of von Willebrand factor and platelet aggregating factor. J Lab Clin Med 1975; 85: 318-328
    PubMedGoogle Scholar
  • 4 Macfarlane DE, Stibbe J, Kirby EP, Zucker MB, Grant RA, McPherson J. A method for assaying von Willebrand factor (ristocetin cofactor). Thromb Diath Haemorrh 1975; 34: 306-308
    PubMedGoogle Scholar
  • 5 Grant RA, Zucker MB, McPherson J. ADP-induced inhibition of von Willebrand factor mediated platelet agglutination. Am J Physiol 1976; 230: 1406-1410
    PubMedGoogle Scholar
  • 6 Zucker MB, Puszkin EG, Sussman II, Mauss EA. Inhibition of von Willebrand factor-induced platelet agglutination by ADP does not result from reduced binding of total von Willebrand factor or its large multimers. J Lab Clin Med 1990
    PubMedGoogle Scholar
  • 7 Mills DCB, Hunchak K, Karl DW, Kirby EP. Effect of platelet activation on the agglutination of platelets by von Willebrand factor. Mol Pharmacol 1990; 37: 271-277
    PubMedGoogle Scholar
  • 8 George JN, Torres MM. Thrombin decreases von Willebrand factor binding to platelet glycoprotein Ib. Blood 1988; 71: 1253-1259
    PubMedGoogle Scholar
  • 9 Coller BS. Inhibition of von Willebrand factor-dependent platelet function by increased platelet cyclic AMP and its prevention by cytoskeletal-disrupting agents. Blood 1981; 57: 846-855
    PubMedGoogle Scholar
  • 10 Moake JL, Tang SS, Olson JD, Troll JH, Cimo PL, Davies PJA. Platelets, von Willebrand factor, and prostaglandin I2. Am J Physiol 1981; 241: H54-H59
    PubMedGoogle Scholar
  • 11 Fox JEB, Phillips DR. Inhibition of actin polymerization in blood platelets by cytochalasins. Nature 1981; 292: 650-652
    CrossrefPubMedGoogle Scholar
  • 12 Puszkin EG, Mauss EA, Zucker MB. Assembly and GPIIIa content of cytoskeletal core in platelets agglutinated with bovine von Willebrand factor. Blood 1990; 76: 1572
    PubMedGoogle Scholar
  • 13 Zucker MB, Mauss EA. Modification of platelet functions by monobromobimane, a fluorescent thiol group label. Thromb Haemos-tas 1986; 55: 228-234
    PubMedGoogle Scholar
  • 14 Nachmias V, Sullender J, Asch A. Shape and cytoplasmic filaments in control and lidocaine-treated human platelets. Blood 1977; 50: 39-53
    PubMedGoogle Scholar
  • 16 Nachmias VT, Sullender JS, Fallon JR. Effects of local anesthetics on human platelets: filopodial suppression and endogenous proteolysis. Blood 1979; 53: 63-72
    PubMedGoogle Scholar
  • 16 Coller BS. Effects of tertiary amine local anesthetics on von Willebrand factor-dependent platelet function: alteration of membrane reactivity and degradation of GPIb by a calcium-dependent pro-tease(s). Blood 1982 60. 731-743
    PubMedGoogle Scholar
  • 17 Solum NO, Olsen TM, Gogstad GO, Hagen I, Brosstad F. Demonstration of a new glycoprotein Ib-related component in platelet extracts prepared in the presence of leupeptin. Biochim Biophys Acta 1983; 729: 53-61
    CrossrefPubMedGoogle Scholar
  • 18 Jefferson JR, Harmon JT, Jamieson GA. Identification of high-affinity (Kd 0.35 Μmol/1) and low affinity (Kd 7.9 Μmol/1) platelet binding sites for ADP and competition by ADP analogues. Blood 1988; 71: 110-116
    PubMedGoogle Scholar
  • 19 Berridge MJ. Inositol triphosphate and diacylglycerol: Two interacting second messengers. Annu Rev Biochem 1987; 56: 159-193
    CrossrefPubMedGoogle Scholar
  • 20 Kroll MH, Schafer AI. Biochemical mechanisms of platelet activation. Blood 1989; 74: 1181-1195
    PubMedGoogle Scholar
  • 21 Drummond AH, MacIntyre DE. Platelet inositol lipid metabolism and calcium flux. In: Platelets in Biology and Pathology III MacIntyre DE, Gordon JG. (eds). Elsevier Science Publishers B.V.; Amsterdam: 1987: 373-431
  • 22 Feinstein MB, Fraser C. Human platelet secretion and aggregation induced by calcium ionophores. Inhibition by PGE1 and dibutyryl cyclic AM, P Gen Physiol 1975 66. 561-581
    PubMedGoogle Scholar
  • 23 Castagna M, Takai Y, Kaibuchi K, Sano K, Kikkawa U, Nishizuka Y. Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters. J Biol Chem 1982; 257: 7847-7851
    PubMedGoogle Scholar
  • 24 Daniel JL, Dangelmaier CA, Selak M, Smith BJ. ADP stimulates IP3 formation in human platelets. FEBS Lett 1986; 206: 299-303
    CrossrefPubMedGoogle Scholar
  • 25 Jones GD, Gear ARL. Subsecond calcium dynamics in ADP- and thrombin-stimulated platelets: A continuous-flow approach using indo-1. Blood 1988; 71: 1539-1543
    PubMedGoogle Scholar
  • 26 Casella JF, Flanagan MD, Lin S. Cytochalasin D inhibits actin polymerization and induces depolymerization of actin filaments formed during platelet shape change. Nature 1981; 293: 302-305
    CrossrefPubMedGoogle Scholar
  • 27 Feinstein MB, Egan JJ, Opas EE. Reversal of thrombin-induced myosin phosphorylation and the assembly of cytoskeletal structures in platelets by the adenylate cyclase stimulants prostaglandin D2 and forskolin. J Biol Chem 1983; 258: 1260-1267
    PubMedGoogle Scholar
  • 28 Cox AC, Carroll RC, White JG, Rao GH. Recycling of platelet phosphorylation and cytoskeletal assembly. J Cell Biol 1984; 98: 8-15
    CrossrefPubMedGoogle Scholar
  • 29 Zilla P, Groscurth P, Varga G, Fischlein T, Fasol R. PGI2 and PGE1 induce morphological alterations in human platelets similar to those of the initial phase of activation. Exp Hematol 1987; 15: 741-749
    PubMedGoogle Scholar
  • 30 Spangenberg P, Till U, Gschmeissner S, Crawford N. Changes in the distribution and organization of platelet actin induced by diamide and its functional consequences. Br J Haematol 1987; 67: 443-450
    CrossrefPubMedGoogle Scholar
  • 31 Solum NO, Olsen TM. Effects of diamide and dibucaine on platelet GP lb, actin-binding protein and cytoskeleton. Biochim Biophys Acta 1985; 817: 249-260
    CrossrefPubMedGoogle Scholar
  • 132 Kalomiris EL, Coller BS. Thiol-specific probes indicate that the 13-chain of platelet glycoprotein lb is a transmembrane protein with a reactive endofacial sulfhydryl group. Biochemistry 1985; 24: 5430-5436
    CrossrefPubMedGoogle Scholar
  • 33 Boyles JK, Fox JEB, Bemdt MC. The distribution of GPIb and the stability of the plasma membrane are dependent upon an intact membrane skeleton. Thromb Haemostas 1987; 58: 225
    PubMedGoogle Scholar
  • 35 Bemdt M. A multi-functional receptor which controls haemostasis. Today’s Life Sci July 1989; 20-25
    PubMedGoogle Scholar
  • 35 Bemdt MC, Fournier DJ, Castaldi PA. Bemard-Soulier syndrome. Bailliére’s Clin Haematol 1989 2. 585-607
    PubMedGoogle Scholar